We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says It Is Cutting Backlog of Postmarketing Studies
FDA Says It Is Cutting Backlog of Postmarketing Studies
September 16, 2009
Drug and biologics makers are on schedule with most postmarketing clinical trials and studies, but while the FDA misses its review deadlines more than half the time, some criticism of its oversight is undeserved, a consulting firm report says.